ClinicalTrials.gg
Active, not recruitingNCT06263985Updated Feb 16, 2024

Axis(TM) Solvent-dehydrate Dermal Allograft in the Treatment of Pelvic Organ Prolapse.

A Phase 4 interventional study of Axis Dermis biologic mesh repair for pelvic organ prolapse in Pelvic Organ Prolapse, sponsored by Michigan Institution of Women's Health PC. Active, not recruiting at 1 site in United States. Open to female participants aged 21 Years to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-16.

Sponsored by Michigan Institution of Women's Health PC · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as active, not recruiting.
  • Registered 2 years 2 months after the study started (first participant enrolled Nov 2021, registered Feb 2024).
Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
21 Years to 89 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 195 studies in Pelvic Organ Prolapse with a site in United States — 12 open to participants now, 23 under way, none of them phase 3. Pelvic Organ Prolapse · United States.

Enrollment
97th of 133
50 · median 78
Started
2021
with 14 others
Phase 4
25 of 195
2 open now
Primary completion
2025-05
later than 3 of 22 live
Registered
180th of 195
by date

Among the 195 studies in Pelvic Organ Prolapse with a site in United States, this one is the 97th largest by enrollment of the 133 interventional ones that give a count, is one of 15 that started in 2021, is one of 25 in phase 4, reaches primary completion later than 3 of the 22 other live ones, and was the 180th registered.

Pelvic Organ Prolapse

521 studies on the registry are indexed under Pelvic Organ Prolapse; 80 are open to participants now.

Browse Pelvic Organ Prolapse studies →

Open to participants now

12 of the 195 studies in Pelvic Organ Prolapse with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Pelvic Organ Prolapse studies recruiting now, 31 (58%) set no upper age limit and 10 (19%) stop at 75 or younger; 2 take children under 18; 14 take healthy volunteers.

This study: 21 Years to 89 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Pelvic Organ Prolapse with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to assess improvement in subjects who have undergone Axis Dermis, biologic mesh for pelvic organ prolapse repair. [describe participant population/health conditions]. The main question[s] it aims to answer are:

  • Is the leading edge of the prolapse above the hymen
  • Does subject notice a bulge Participants will undergo Axis Dermis pelvic organ prolapse repair procedure.
Read the detailed description

This is a prospective single-arm study of 50 subjects undergoing pelvic organ prolapse repair using the Axis™ Dermis biologic mesh. They will be followed for a period of 3 years. A subgroup analysis is for patients with uterine prolapse and vaginal mesh hysteropexy.

Clinical examination including vaginal wall retraction with or without pelvic ultrasound, POP-Q, and also specific validated questionnaires at baseline, 1 month, 6 month, 12 month, 24 month and 36 month visits will be assessed.

03

Conditions studied

  • Pelvic Organ Prolapse

Browse trials for

04

Who can participate

Ages eligible
21 Years to 89 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with preoperative stage II or greater prolapse on the Pelvic Organ Prolapse Quantification System Assessment (POP-Q)
  • Subjects who have bothersome vaginal bulge based upon symptoms.
  • Subjects who undergo any type of Axis Dermis surgery (anterior, posterior, total, with or without a uterus).

Exclusion criteria

Exclusion Criteria:

  • Subjects who are unable to follow-up.
  • Subjects who cannot complete the validated questionnaires.
  • Subjects that lack competency of the English language.
  • Subjects who decline to be part of the clinical trial.
  • Subjects who do not sign an .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Other
    Subjects undergoing a pelvic organ prolapse repair procedure using Axis Dermis biologic mesh

    This is a single are which will be composed of subjects with Stage II or greater pelvic organ prolapse who have agreed to undergoing a pelvic organ prolapse repair procedure using Axis Dermis biologic mesh. They will undergo the procedure and be followed for a period of 3 years.

    Device: Axis Dermis biologic mesh repair for pelvic organ prolapse

Interventions

  • DeviceAxis Dermis biologic mesh repair for pelvic organ prolapse

    Subjects with pelvic organ prolapse will undergo a pelvic organ prolapse repair with the use of Axis Dermis biologic mesh.

06

What researchers measure

Primary outcomes

  1. Improvement in function

    Determine improvement in function based on questionnaire Pelvic Floor Distress Inventory Q#3 "Do you usually have a bulge or something falling out that you can see or fell in the vaginal area?" Answered No, or if Yes: Not at all bothersome.

    Time frame: Preoperative to 3 years postoperative.

  2. Improvement in Anatomy

    To assess improvement in anatomy with success defined as the leading edge of the prolapse is above the hymen, and no reintervention (surgery or pessary) for pelvic organ prolapse.

    Time frame: Preoperative to 3 years postoperative.

Secondary outcomes

  1. Assess complications or untoward side effects.

    Assessment of intraoperative complications (such as bleeding and injuries) and post operative complications (such as de novo incontinence, de novo dyspareunia, recurrent urinary tract infections, voiding dysfunction and effect on untreated vaginal wall).

    Time frame: intraoperative to 3 years postoperative

07

Study locations

1 site
  • Advanced Urogynecology of Michigan
    Dearborn, Michigan 48124, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for May 2025, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2024
First posted
Feb 16, 2024
StartActual
Nov 2, 2021
Primary completionEst.
May 30, 2025
CompletionEst.
May 30, 2025
Last update
Feb 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06263985
Lead sponsor
Michigan Institution of Women's Health PC
Collaborators
Coloplast A/S
Responsible party
Salil Khandwala (Medical director, Michigan Institution of Women's Health PC) — Principal investigator
First posted
Feb 16, 2024
Start date
Nov 2, 2021
Primary completion
May 30, 2025 (estimated)
Completion
May 30, 2025 (estimated)
Last update
Feb 16, 2024

Study contacts

Salil Khandwala, MD
principal investigator · Michigan Institution of Women's Health PC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion